Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.41 |
| ▸ | MITF | O75030 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.41 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.41 |
| ▸ | XBP1 | P17861 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4918556 | 1.00 | CHRM2 (0.54) | CHRM2CA12CA1CA2CA4 | |
| SCHEMBL4914707 | 0.97 | CHRM2 (0.53) | CHRM2CA12CA1CA2CA4 | |
| SCHEMBL4913677 | 0.85 | CHRM2 (0.50) | CHRM2CA12CA1CA2CA9 | |
| SCHEMBL4916801 | 0.85 | CHRM2 (0.50) | CHRM2CA12CA1CA2CA9 | |
| SCHEMBL4908817 | 0.82 | CHRM2 (0.58) | CHRM2MEN1KMT2ATAAR1SCN8A | |
| SCHEMBL4916809 | 0.82 | CHRM2 (0.58) | CHRM2MEN1KMT2ATAAR1SCN8A | |
| SCHEMBL4919093 | 0.81 | MEN1 (0.53) | CHRM2GAAMEN1KMT2A | |
| SCHEMBL4913834 | 0.81 | MEN1 (0.53) | CHRM2GAAMEN1KMT2A | |
| SCHEMBL4917452 | 0.81 | CHRM2 (0.49) | CHRM2CA12CA1CA2CA9 | |
| SCHEMBL4916759 | 0.81 | CHRM2 (0.74) | CHRM2CA12CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3390483-B1 | ENCAPSULATION | PROCTER & GAMBLE (US) | 2022-05-18 | — | — | EP | disclosed |
| EP-3368207-B1 | ENCAPSULATION | ENCAPSYS LLC (US) | 2021-12-01 | — | — | EP | disclosed |
| US-10864167-B2 | Encapsulation | THE PROCTER & GAMBLE COMPANY (US) | 2020-12-15 | — | — | US | disclosed |
| EP-3390483-A1 | ENCAPSULATION | The Procter and Gamble Company (US) | 2018-10-24 | — | — | EP | disclosed |
| EP-3368207-A1 | ENCAPSULATION | ENCAPSYS, LLC (US) | 2018-09-05 | — | — | EP | disclosed |
| US-20180235893-A1 | ENCAPSULATION | THE PROCTER & GAMBLE COMPANY | 2018-08-23 | — | — | US | disclosed |
| US-9937477-B2 | Encapsulation | WATERTITE PRODUCTS, INC. | 2018-04-10 | — | — | US | disclosed |
| EP-1914254-B1 | Crosslinkers for improving stability of polyurethane foams | EVONIK DEGUSSA GMBH (DE) | 2017-08-23 | — | — | EP | disclosed |
| WO-2017074995-A1 | ENCAPSULATION | ENCAPSYS, LLC (US) | 2017-05-04 | — | — | WO | disclosed |
| WO-2017074997-A1 | ENCAPSULATION | ENCAPSYS, LLC (US) | 2017-05-04 | — | — | WO | disclosed |
| US-20170113200-A1 | Encapsulation | Encapsys,LLC (US) | 2017-04-27 | — | — | US | disclosed |
| US-8552078-B2 | Non-fugitive tertiary amine catalyst and alkylated polyamine crosslinking additives; aging resistance | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2013-10-08 | — | — | US | disclosed |
| EP-1914254-A1 | Crosslinkers for improving stability of polyurethane foams | Air Products and Chemicals, Inc. (US) | 2008-04-23 | — | — | EP | disclosed |
| US-20080090922-A1 | Crosslinkers for improving stability of polyurethane foams | EVONIK OPERATIONS GMBH (DE) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180235893-A1 | ENCAPSULATION | ACR, ACMSD, SAMM50 | CHRM2 1120/4885CA12 3244/4885CA1 3522/4885 |
| US-10864167-B2 | Encapsulation | ACR, MPHOSPH6, ACMSD | CHRM2 993/4885CA12 3364/4885CA1 3707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.